Deal Details

Reata Completes $505.1 Million Follow-On Offering

Healthcare

Reata follow-on offering

Summary

Reata Pharmaceuticals, Inc. ("Reata” or the "Company”) (NASDAQ: RETA) recently completed an underwritten public offering of 2,760,000 shares of its common stock, including 360,000 shares sold upon full exercise of the overallotment option, at a price to the public of $183.00 per share. The gross proceeds to Reata from the offering are expected to be $505.1 million.

Baird served as co-manager on this offering.

About

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. The Company's two most advanced clinical candidates, bardoxolone methyl (bardoxolone) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency. Reata is headquartered in Plano, Texas.

Healthcare

Reata follow-on offering